Tango's Stock Hits Record High on Erasca Collaboration, But Valuation Risks Persist

What happened

Tango Therapeutics' stock surged to a record high after inking a clinical collaboration with Erasca to test vopimetostat in combination with ERAS-0015 for MTAP-deleted RAS-mutant cancers, aiming to expand its therapeutic reach. This deal adds optionality by exploring combo regimens in a tough-to-treat patient subset, potentially broadening vopimetostat's market beyond its current pancreatic and lung cancer focus. However, Tango remains pre-revenue and heavily dependent on vopimetostat's pivotal trial success, with a market cap around $1.38B that already prices in substantial clinical achievements. The DeepValue report highlights persistent risks, including cash burn into 2028 without recurring revenue, competition from Amgen's AMG 193, and reliance on a single-arm pivotal design for regulatory approval. While the collaboration signals strategic activity, it does not immediately de-risk the core investment thesis centered on vopimetostat's monotherapy outcomes.

Implication

For investors, this news-driven rally should be viewed cautiously, as it reflects sentiment rather than substantive de-risking of Tango's high-stakes clinical and financial profile. The collaboration introduces a new clinical avenue that could enhance vopimetostat's utility long-term, but it requires additional funding and data, adding operational complexity without alleviating near-term cash concerns. The DeepValue report underscores that without successful pivotal data by 2026, the stock's valuation could re-rate toward net cash levels, implying over 40% downside from current levels. Monitoring upcoming milestones like the pivotal trial start and cash guidance is critical, as any delays or disappointments would likely trigger a sharp correction. Given the elevated price and unchanged core risks, the prudent stance remains to trim positions above $15 and await better entry points or clearer clinical validation.

Thesis delta

The Erasca collaboration modestly shifts the thesis by adding combination therapy optionality, which could improve vopimetostat's competitive positioning if data are positive. However, it does not materially alter the high dependence on monotherapy pivotal success, cash runway pressures, or competitive threats from Amgen, keeping the overall investment thesis as a potential sell with heightened execution risk. Investors should continue to prioritize the 2026 pivotal trial initiation and data updates as the primary drivers for any meaningful thesis change.